Latest news

• Novo Nordisk signs deal for Prothena's heart drug worth up to $1.2bn

  Initially, Novo will focus on the clinical development of Prothena’s antibody PRX004 in ATTR cardiomyopathy. ... Initially, Novo will focus on the clinical development of Prothena’s antibody PRX004 in ATTR cardiomyopathy, an underdiagnosed and

• Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy

  placebo in patients with ATTR cardiomyopathy, reducing the death rate from around 43% to 29.5%. ... Prior to Vyndaqel, treatment options for patients with ATTR cardiomyopathy were restricted to symptom management and – in rare cases – a heart

• Vyndaqel a bright spot as Pfizer comes under pressure

  following its FDA approval to treat ATTR cardiomyopathy last September. ... As of the end of 2019 more than 9, 000 ATTR cardiomyopathy patients had been diagnosed in the US – raising the diagnosis rate from 1% pre-Vyndaqel launch to around 9%,

• Pfizer buys dwarfism drug company Therachon for $810m

  The deal adds to Pfizer’s rare disease portfolio, which just chalked up a major success with the approval of tafamidis products Vyndaqel and Vyndamax for transthyretin amyloid cardiomyopathy (ATTR-CM)

• Speedy approval for Pfizer's Onpattro rival

  Approved in two different formulations. Pfizer’s blockbuster-in-waiting drug tafamidis has gained FDA approval to treat cardiomyopathy in patients with rare disease ATTR. ... Cardiomyopathy (CM) is the most serious of the symptoms seen in patients with